Scinai Immunotherapeutics Ltd (SCNI) ADR Each Representing 400 Ord Shares SPON

Sell:$3.46Buy:$3.70$0.09 (2.43%)

Prices delayed by at least 15 minutes
Sell:$3.46
Buy:$3.70
Change:$0.09 (2.43%)
Deal now
Prices delayed by at least 15 minutes
Sell:$3.46
Buy:$3.70
Change:$0.09 (2.43%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Key people

Mark S. Germain
Chairman of the Board
Amir Reichman
Chief Executive Officer, Director
Uri Ben-Or
Chief Financial Officer
Elad Mark
Chief Operating Officer
Tamar Ben-Yedidia
Chief Scientific Officer
Jay Green
Director
Samuel J. Moed
Director
Avner Rotman
Director
Morris C. Laster
Independent Director
Yael Margolin
External Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Israel
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09073Q3039
  • Market cap
    $3.00m
  • Employees
    31
  • Shares in issue
    3.41bn
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.